Literature DB >> 32882179

Valproic Acid Thermally Destabilizes and Inhibits SpyCas9 Activity.

Xinlai Cheng1.   

Abstract

The clustered regularly interspaced short palindromic repeat (CRISPR)-Cas9 system plays an important role in prokaryotic adaptive immunity. Due to its capacity for sequence-specific gene editing, CRISPR-Cas9 has become one of the most important tools widely used for genome editing in molecular biotechnology. However, its clinical application is currently limited by unwanted mutations at off-target sites. Various strategies have been developed for precise control of Cas9 in order to reduce these off-target effects, including chemical-based approaches. From a chemical screening, I observed that valproic acid (VPA) binds to and destabilizes Streptococcus pyogenes Cas9 (SpyCas9) protein in vitro, as well as in cells, while within its therapeutical concentration range under conditions of hyperthermia as demonstrated. Conditions were generated either by an external heat bag or in combination with the photothermal therapeutic agent indocyanine green activated by a near-infrared laser. Use of other histone deacetylase inhibitors failed, suggesting a histone deacetylase inhibition-independent function of VPA. Thus, this finding provides an uncomplicated thermotherapeutical approach for timely regulation of the activity of the CRISPR-Cas9 system at desired locations.
Copyright © 2020 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRISPR-Cas9; Cas9 degrader; Cas9 inhibitor; gene therapy; genome editing; off-target; selectivity; thermal stability; valproic acid

Year:  2020        PMID: 32882179      PMCID: PMC7704752          DOI: 10.1016/j.ymthe.2020.08.014

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  41 in total

1.  When genome editing goes off-target.

Authors:  Hannah R Kempton; Lei S Qi
Journal:  Science       Date:  2019-04-18       Impact factor: 47.728

Review 2.  High-throughput functional genomics using CRISPR-Cas9.

Authors:  Ophir Shalem; Neville E Sanjana; Feng Zhang
Journal:  Nat Rev Genet       Date:  2015-04-09       Impact factor: 53.242

Review 3.  The next generation of CRISPR-Cas technologies and applications.

Authors:  Adrian Pickar-Oliver; Charles A Gersbach
Journal:  Nat Rev Mol Cell Biol       Date:  2019-08       Impact factor: 94.444

4.  Rationally engineered Cas9 nucleases with improved specificity.

Authors:  Ian M Slaymaker; Linyi Gao; Bernd Zetsche; David A Scott; Winston X Yan; Feng Zhang
Journal:  Science       Date:  2015-12-01       Impact factor: 47.728

5.  A High-Throughput Platform to Identify Small-Molecule Inhibitors of CRISPR-Cas9.

Authors:  Basudeb Maji; Soumyashree A Gangopadhyay; Miseon Lee; Mengchao Shi; Peng Wu; Robert Heler; Beverly Mok; Donghyun Lim; Sachini U Siriwardena; Bishwajit Paul; Vlado Dančík; Amedeo Vetere; Michael F Mesleh; Luciano A Marraffini; David R Liu; Paul A Clemons; Bridget K Wagner; Amit Choudhary
Journal:  Cell       Date:  2019-05-02       Impact factor: 41.582

Review 6.  Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain.

Authors:  W Löscher
Journal:  Neurochem Res       Date:  1993-04       Impact factor: 3.996

7.  Highly efficient biallelic genome editing of human ES/iPS cells using a CRISPR/Cas9 or TALEN system.

Authors:  Kazuo Takayama; Keisuke Igai; Yasuko Hagihara; Rina Hashimoto; Morifumi Hanawa; Tetsushi Sakuma; Masashi Tachibana; Fuminori Sakurai; Takashi Yamamoto; Hiroyuki Mizuguchi
Journal:  Nucleic Acids Res       Date:  2017-05-19       Impact factor: 16.971

8.  Targeting repair pathways with small molecules increases precise genome editing in pluripotent stem cells.

Authors:  Stephan Riesenberg; Tomislav Maricic
Journal:  Nat Commun       Date:  2018-06-04       Impact factor: 14.919

9.  Imidazopyridines as Potent KDM5 Demethylase Inhibitors Promoting Reprogramming Efficiency of Human iPSCs.

Authors:  Yasamin Dabiri; Rodrigo A Gama-Brambila; Katerina Taškova; Kristina Herold; Stefanie Reuter; James Adjaye; Jochen Utikal; Ralf Mrowka; Jichang Wang; Miguel A Andrade-Navarro; Xinlai Cheng
Journal:  iScience       Date:  2019-01-11

10.  Inhibition of histone deacetylase 1 (HDAC1) and HDAC2 enhances CRISPR/Cas9 genome editing.

Authors:  Bin Liu; Siwei Chen; Anouk La Rose; Deng Chen; Fangyuan Cao; Martijn Zwinderman; Dominik Kiemel; Manon Aïssi; Frank J Dekker; Hidde J Haisma
Journal:  Nucleic Acids Res       Date:  2020-01-24       Impact factor: 16.971

View more
  1 in total

Review 1.  Small Molecules for Enhancing the Precision and Safety of Genome Editing.

Authors:  Siyoon Shin; Seeun Jang; Donghyun Lim
Journal:  Molecules       Date:  2022-09-23       Impact factor: 4.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.